Table 2.

Sunitinib and dasatinib inhibit brain metastases in preclinical models

	231-Br-HER2+ model					231-Br-HER2− model
Treatment	N	Large metastases mean (95% CI)	P	Micro metastases mean (95% CI)	P	N	Large metastases mean (95% CI)	P	Micro metastases mean (95% CI)	P
Vehicle	18	20 (18–23)	ref	293.6 (255.1–332.1)	ref	19	15 (12–17)	ref	218.3 (185.3–251.3)	ref
Sunitinib 80 mg/kg	17	14 (12–15)	0.02	199.8 (175.7–223.9)	0.05	16	10 (9–11)	0.03	150.2 (128.2–177.2)	0.06
Sunitinib 40 mg/kg	16	16 (14–18)	0.05	228.1 (199.8–256.4)	0.07	17	12 (10–14)	0.08	156.1 (131.1–181.1)	0.05
Dasatinib 50 mg/kg	14	9 (7–10)	0.02	113.2 (89.4–137)	0.01	16	8 (6–8)	0.02	99.5 (89.2–109.8)	0.009
Dasatinib 25 mg/kg	15	13 (11–14)	0.04	175.7 (147.9–203.5)	0.04	18	9 (7–10)	0.03	144.6 (132.1–157.1)	0.012

NOTE: Mice were injected with 1.75 × 10⁵ 231-Br-HER2+ or 231-Br-HER2− cells through the left ventricle and treated with sunitinib, dasatinib, or vehicle starting three days later. The treatment was carried out once daily for 28 days. Numbers of metastases were determined in 10-step sections from each mouse brain described in Materials and Methods. CI, confidence interval. For each group of data, the normality was examined with the Jarque–Bera test first, and then Levene F test was used to test multigroup HOV. If the groups enrolled followed the HOV, the Student t test was used for analyzing experimental data; if not, the Wilcoxon rank test was executed. All P values are two-sided.